Sökning: onr:"swepub:oai:DiVA.org:uu-430293" >
Cost-effectiveness ...
-
Landmesser, Ulf
(författare)
Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
2020-10-16
-
Oxford University Press (OUP),2022
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-430293
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-430293URI
-
https://doi.org/10.1093/ehjqcco/qcaa072DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:148600068URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Aims: To assess the cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab added to standard-of-care lipid-lowering treatment [maximum tolerated dose (MTD) of statin and ezetimibe] in Swedish patients with a history of myocardial infarction (MI).Methods and results: Cost-effectiveness was evaluated using a Markov model based on Swedish observational data on cardiovascular event rates and efficacy from the FOURIER trial. Three risk profiles were considered: recent MI in the previous year; history of MI with a risk factor; and history of MI with a second event within 2 years. For each population, three minimum baseline low-density lipoprotein cholesterol (LDL-C) levels were considered: 2.5 mmol/L (≈100 mg/dL), based on the current reimbursement recommendation in Sweden; 1.8 mmol/L (≈70 mg/dL), based on 2016 ESC/EAS guidelines; and 1.4 mmol/L (≈55 mg/dL), or 1.0 mmol/L (≈40 mg/dL) for MI with a second event, based on 2019 ESC/EAS guidelines. Proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab was associated with increased quality-adjusted life-years and costs vs. standard-of-care therapy. Incremental cost-effectiveness ratios (ICERs) were below SEK700 000 (∼€66 500), the generally accepted willingness-to-pay threshold in Sweden, for minimum LDL-C levels of 2.3 (recent MI), 1.7 (MI with a risk factor), and 1.7 mmol/L (MI with a second event). Sensitivity analyses demonstrated that base-case results were robust to changes in model parameters.Conclusion: Proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab added to MTD of statin and ezetimibe may be considered cost-effective at its list price for minimum LDL-C levels of 1.7–2.3 mmol/L, depending on risk profile, with ICERs below the accepted willingness-to-pay threshold in Sweden.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Lindgren, PeterKarolinska Institutet
(författare)
-
Hagström, EmilUppsala universitet,Kardiologi(Swepub:uu)emhag677
(författare)
-
van Hout, Ben
(författare)
-
Villa, Guillermo
(författare)
-
Pemberton-Ross, Peter
(författare)
-
Arellano, Jorge
(författare)
-
Svensson, Maria K.Uppsala universitet,Njurmedicin,Medical Affairs, Amgen AB, Gustav III: s Boulevard 54, 169 74, Solna, Sweden.(Swepub:uu)marsv604
(författare)
-
Sibartie, Mahendra
(författare)
-
Fonarow, Gregg C
(författare)
-
Svensson, ME
(författare)
-
Karolinska InstitutetKardiologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:European Heart Journal - Quality of Care and Clinical Outcomes: Oxford University Press (OUP)8:1, s. 31-382058-52252058-1742
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Landmesser, Ulf
-
Lindgren, Peter
-
Hagström, Emil
-
van Hout, Ben
-
Villa, Guillermo
-
Pemberton-Ross, ...
-
visa fler...
-
Arellano, Jorge
-
Svensson, Maria ...
-
Sibartie, Mahend ...
-
Fonarow, Gregg C
-
Svensson, ME
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
European Heart J ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet